<DOC>
	<DOC>NCT00965757</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of T-614 versus placebo when added to ongoing, stable-dose methotrexate therapy in patients with persistently active rheumatoid arthritis</brief_summary>
	<brief_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion criteria: Subjects who have a diagnosis of Rheumatoid Arthritis by the ACR criteria Age greater or 20 years and less than 70 years old Exclusion criteria: Subject who is considered by the investigator, for any reason, to be an unsuitable candidate for the study Women of childbearing potential who are not practicing a successful method of contraception, or wish to become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>